Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

23 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Plerixafor and G-CSF combination mobilizes hematopoietic stem and progenitors cells with a distinct transcriptional profile and a reduced in vivo homing capacity compared to plerixafor alone.
Lidonnici MR, Aprile A, Frittoli MC, Mandelli G, Paleari Y, Spinelli A, Gentner B, Zambelli M, Parisi C, Bellio L, Cassinerio E, Zanaboni L, Cappellini MD, Ciceri F, Marktel S, Ferrari G. Lidonnici MR, et al. Among authors: zanaboni l. Haematologica. 2017 Apr;102(4):e120-e124. doi: 10.3324/haematol.2016.154740. Epub 2016 Dec 29. Haematologica. 2017. PMID: 28034992 Free PMC article. No abstract available.
An update on iron chelation therapy.
Poggiali E, Cassinerio E, Zanaboni L, Cappellini MD. Poggiali E, et al. Among authors: zanaboni l. Blood Transfus. 2012 Oct;10(4):411-22. doi: 10.2450/2012.0008-12. Epub 2012 Jun 27. Blood Transfus. 2012. PMID: 22790257 Free PMC article. Review. No abstract available.
Thyroid cancer in β-thalassemia.
Baldini M, Serafino S, Zanaboni L, Cappellini MD. Baldini M, et al. Among authors: zanaboni l. Hemoglobin. 2012;36(4):407-8. doi: 10.3109/03630269.2012.695308. Epub 2012 Jun 8. Hemoglobin. 2012. PMID: 22680613 No abstract available.
Randomized phase II trial of deferasirox (Exjade, ICL670), a once-daily, orally-administered iron chelator, in comparison to deferoxamine in thalassemia patients with transfusional iron overload.
Piga A, Galanello R, Forni GL, Cappellini MD, Origa R, Zappu A, Donato G, Bordone E, Lavagetto A, Zanaboni L, Sechaud R, Hewson N, Ford JM, Opitz H, Alberti D. Piga A, et al. Among authors: zanaboni l. Haematologica. 2006 Jul;91(7):873-80. Haematologica. 2006. PMID: 16818273 Clinical Trial.
23 results